Research programme: immunocytokine anti-cancer therapeutics - Provenance

Drug Profile

Research programme: immunocytokine anti-cancer therapeutics - Provenance

Alternative Names: Anti-CSPG4-IL2; Anti-EpCAM-IL2

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Provenance Biopharmaceuticals
  • Class Antibodies; Antineoplastics; Cytokines; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma; Neuroblastoma; Prostate cancer

Most Recent Events

  • 06 Sep 2017 Preclinical trials in Neuroblastoma in USA (Parenteral)
  • 06 Sep 2017 Pharmacodynamics data from a preclinical study in Neuroblastoma presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)
  • 05 May 2014 Preclinical trials in Prostate cancer in USA (Parenteral) prior to May 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top